Sana Biotechnology
| Biotechnology | |
| ISIN | 🆔 |
| Founded 📆 | |
| Founder 👔 | Steve Harr |
| Headquarters 🏙️ | Seattle, WA, |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | https://sana.com/ |
| 📇 Address | |
| 📞 telephone | |
Sana Biotechnology is an biotechnology company creating and delivering in vivo and ex vivo cell therapies and gene therapies. The company is making capabilities around making cells at scale ex vivo, in vivo delivery, hide allogeneic cells, controllable gene and protein expression systems, manufacturing, and research and development.[1]
Funding[edit]
On June 23, 2020, Sana received $700 million for an initial funding round by venture capital firms Arch Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV, Omega Funds, Altitude Life Science Ventures. They also received ex-financial and research team from Juno Therapeutics including Sunil Agarwal, M.D.[2]
- ↑ "Giving highly funded but secretive Moderna a run for its money, Juno-lite Sana raises $700M". FierceBiotech. Retrieved 2020-06-30.
- ↑ "Giving highly funded but secretive Moderna a run for its money, Juno-lite Sana raises $700M". FierceBiotech. Retrieved 2020-06-30.
References[edit]
This article "Sana Biotechnology" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sana Biotechnology. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
